SurGenTec was granted FDA 510(k) clearance to market their proprietary TiLink-L Sacroiliac Joint Fusion System. The device may be implanted from a lateral or posterior/oblique approach and uses unique surface technology to optimize bone growth. This implant will be SurGenTec’s inaugural “First Implant in the Sacroiliac Family of Products.”
TiLink-L’s design supports compression across the joint. In addition, the implant is equipped with SurGenTec’s proprietary Nanotex surface technology. In vivo studies demonstrated bony in-growth and on-growth, which may enhance stability for improved surgical outcomes.
The product also boasts a helical self-harvesting channel to capture the patient’s own bone and encourage healing. Graft windows are strategically placed between threads to allow for potential fusion through the screw to enhance stability. The system offers a variety of implant lengths, ensuring a custom fit for patients.
“We are thrilled to announce the FDA clearance of our first treatment option in our sacroiliac family of products,” says Travis Greenhalgh, CEO at SurGenTec. “With its unique properties and ability to adapt to diverse patient needs, TiLink-L is set to offer physicians the ability to stabilize the sacroiliac joint in a variety of approaches. Whether in an outpatient or hospital setting, we believe this device is poised to make a significant difference in patient care.”
SurGenTec was granted FDA 510(k) clearance to market their proprietary TiLink-L Sacroiliac Joint Fusion System. The device may be implanted from a lateral or posterior/oblique approach and uses unique surface technology to optimize bone growth. This implant will be SurGenTec’s inaugural “First Implant in the Sacroiliac Family of Products.” ...
SurGenTec was granted FDA 510(k) clearance to market their proprietary TiLink-L Sacroiliac Joint Fusion System. The device may be implanted from a lateral or posterior/oblique approach and uses unique surface technology to optimize bone growth. This implant will be SurGenTec’s inaugural “First Implant in the Sacroiliac Family of Products.”
TiLink-L’s design supports compression across the joint. In addition, the implant is equipped with SurGenTec’s proprietary Nanotex surface technology. In vivo studies demonstrated bony in-growth and on-growth, which may enhance stability for improved surgical outcomes.
The product also boasts a helical self-harvesting channel to capture the patient’s own bone and encourage healing. Graft windows are strategically placed between threads to allow for potential fusion through the screw to enhance stability. The system offers a variety of implant lengths, ensuring a custom fit for patients.
“We are thrilled to announce the FDA clearance of our first treatment option in our sacroiliac family of products,” says Travis Greenhalgh, CEO at SurGenTec. “With its unique properties and ability to adapt to diverse patient needs, TiLink-L is set to offer physicians the ability to stabilize the sacroiliac joint in a variety of approaches. Whether in an outpatient or hospital setting, we believe this device is poised to make a significant difference in patient care.”
Copy to clipboard 
